https://thehill.com/policy/international/china/428181-us-intelligence-accuses-china-of-using-student-spies-to-steal
A new meta-analysis of trials evaluating aspirin for primary prevention of cardiovascular disease has found no overall benefit, with aspirin use associated with a lower risk of cardiovascular events but an increased risk of major bleeding, and no effect of aspirin on cancer risk.
However, there still appears to be some disagreement on how to apply these findings.
"A review of the evidence for use of aspirin in primary prevention was last looked at 5 or 6 years ago but now we have additional data from three new trials published last year — ARRIVE in people at higher CV risk, ASCEND in people with diabetes, and ASPREE in older individuals," lead author of the new meta-analysis, Sean Zheng, BM, BCh, King's College Hospital, London, United Kingdom, told Medscape Medical News.
"This new analysis was done to bring together the total evidence on aspirin in primary prevention of cardiovascular disease now available in a mixed population," he said.
"We found that aspirin did reduce cardiovascular events by a modest 11%, with a number needed to treat to prevent one event of 265, but it also increased major bleeding, such as serious GI bleed, intracranial bleed or bleed needing hospitalization or transfusion by 43%. That is a number needed to harm of 210," Zheng reported.
"These numbers needed to treat for benefit and harm are of similar magnitude," he said. "So there isn't a clear-cut benefit, and in order to make a decision each patient would have to be considered individually with their own personal view of how they value these benefits and risks. But at the population level, we can say this is not strong enough evidence to recommend use of aspirin routinely."
https://twitter.com/Medscape/status/1091774505494687744
https://www.breitbart.com/sports/2019/02/02/patriots-owner-robert-kraft-trump-working-hard-serve-best-interests-of-the-country/